miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma

Lu,Ning; Zhang,Mei; Lu,Lu; Liu,Yan‑Zhao; Zhang,Hai‑Hong; Liu,Xiao‑Dong

doi:10.3892/or.2020.7880

miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma

Authors:
- Ning Lu
- Mei Zhang
- Lu Lu
- Yan‑Zhao Liu
- Hai‑Hong Zhang
- Xiao‑Dong Liu
View Affiliations

Affiliations: Department of Breast Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, P.R. China, Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Medicine, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Human Resources, Tianjin Hospital, Tianjin 300211, P.R. China
Published online on: December 2, 2020 https://doi.org/10.3892/or.2020.7880
Pages: 706-716
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miRNA/mir)‑490‑3p has been defined as a tumor suppressor in different types of cancer, including breast cancer. However, miR‑490‑3p has been shown to function as a tumor suppressor and promoter in a context‑dependent manner in hepatocellular and lung cancer. Contrary to previous studies, the present study revealed that miR‑490‑3p expression was significantly higher in invasive ductal carcinoma (IDC) tissue specimens, the most common form of breast cancer, compared to tumor‑adjacent normal tissue specimens (n=20). Its expression was also higher in the more metastatic breast cancer cell line, MDA‑MB‑231, compared to the non‑metastatic breast cancer cell line, MCF7, and the moderately metastatic breast cancer cell line, MDA‑MB‑468. The expression of miR‑490‑3p was induced following transforming growth factor (TGF)‑β‑induced epithelial‑to‑mesenchymal transition (EMT) in MCF10A cells. Gain‑and loss‑of‑function assays revealed that the expression of miR‑490‑3p regulated the proliferation, colony formation, EMT, migration and invasion in vitro, but not the apoptosis of MDA‑MB‑468 and MDA‑MB‑231 cells. The knockdown of miR‑490‑3p expression in MDA‑MB‑231 cells inhibited experimental metastasis in a tumor xenograft assay. As in lung cancer, miR‑490‑3p was found to target and downregulate the expression of the tumor suppressor RNA binding protein poly r(C) binding protein 1 (PCBP1). PCBP1 protein and miR‑490‑3p expression inversely correlated in patients with ductal carcinoma in situ (DCIS; n=10; no nodal involvement) and IDC (n=10; different stages of metastatic progression) with a significantly higher miR‑490‑3p expression in patients with IDC compared to those with DCIS. The expression of miR‑490‑3p was negatively associated with both overall and disease‑free survival in the patients with breast cancer included in the present study. On the whole, the results confirm a pro‑metastatic role of miR‑490‑3p in IDC, establishing it as a biomarker for disease progression in these patients.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie XM, et al: A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 11:3642011. View Article : Google Scholar : PubMed/NCBI
3	Sporn MB: The war on cancer. Lancet. 347:1377–1381. 1996. View Article : Google Scholar : PubMed/NCBI
4	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sayer HG, Kath R, Kliche KO and Höffken K: Premenopausal breast cancer: Chemotherapy and endocrine therapy. Drugs. 62:2025–2038. 2002. View Article : Google Scholar : PubMed/NCBI
6	de Bono JS, Tolcher AW and Rowinsky EK: The future of cytotoxic therapy: Selective cytotoxicity based on biology is the key. Breast Cancer Res. 5:154–159. 2003. View Article : Google Scholar : PubMed/NCBI
7	Hu S, Wilson KD, Ghosh Z, Wang Y, Lan F, Ransohoff KJ, Burridge P and Wu JC: MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells. 31:259–268. 2013. View Article : Google Scholar : PubMed/NCBI
8	Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y and Archer TK: Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 28:6426–6438. 2008. View Article : Google Scholar : PubMed/NCBI
9	Liu X, He B, Xu T, Pan Y, Hu X, Chen X and Wang S: MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. J Cancer. 9:1218–1230. 2018. View Article : Google Scholar : PubMed/NCBI
10	Chen K, Zeng J, Tang K, Xiao H, Hu J, Huang C, Yao W, Yu G, Xiao W, Guan W, et al: miR-490-5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA. Biol Cell. 108:41–50. 2016. View Article : Google Scholar : PubMed/NCBI
11	Chen S, Chen X, Xiu YL, Sun KX and Zhao Y: MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. Cancer Lett. 362:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
12	Lan G, Yang L, Xie X, Peng L and Wang Y: MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. Arch Med Sci. 11:561–569. 2015. View Article : Google Scholar : PubMed/NCBI
13	Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen H, Mao Y, Lin Y, Luo J, et al: MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 441:976–981. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhang LY, Liu M, Li X and Tang H: miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 288:4035–4047. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ou Y, He J and Liu Y: MiR-490-3p inhibits autophagy via targeting ATG7 in hepatocellular carcinoma. IUBMB Life. 70:468–478. 2018. View Article : Google Scholar : PubMed/NCBI
16	Li J, Feng Q, Wei X and Yu Y: MicroRNA-490 regulates lung cancer metastasis by targeting poly r(C)-binding protein 1. Tumour Biol. 37:15221–15228. 2016. View Article : Google Scholar : PubMed/NCBI
17	Gu H, Yang T, Fu S, Chen X, Guo L and Ni Y: MicroRNA-490-3p inhibits proliferation of A549 lung cancer cells by targeting CCND1. Biochem Biophys Res Commun. 444:104–108. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhao L and Zheng XY: MicroRNA-490 inhibits tumorigenesis and progression in breast cancer. Onco Targets Ther. 9:4505–4516. 2016. View Article : Google Scholar : PubMed/NCBI
19	Zientek-Targosz H, Kunnev D, Hawthorn L, Venkov M, Matsui S, Cheney RT and Ionov Y: Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: A model for identifying candidate breast-tumor suppressors. Mol Cancer. 7:512008. View Article : Google Scholar : PubMed/NCBI
20	Cailleau R, Olivé M and Cruciger QV: Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization. In Vitro. 14:911–915. 1978. View Article : Google Scholar : PubMed/NCBI
21	Brünner N, Boysen B, Rømer J and Spang-Thomsen M: The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat. 24:257–264. 1993. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL and Howe PH: TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 12:286–293. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MC, Merrick WC and Howe PH: Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 41:419–431. 2011. View Article : Google Scholar : PubMed/NCBI
25	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
26	Unberath P, Knell C, Prokosch HU and Christoph J: Developing new analysis functions for a translational research platform: Extending the cbioportal for cancer genomics. Stud Health Technol Inform. 258:46–50. 2019.PubMed/NCBI
27	Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
28	Wu HT, Zhong HT, Li GW, Shen JX, Ye QQ, Zhang ML and Liu J: Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer. J Transl Med. 18:512020. View Article : Google Scholar : PubMed/NCBI
29	Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, et al: miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 6:e169152011. View Article : Google Scholar : PubMed/NCBI
30	Zhang ZZ, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, Cao H and Xu J: HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of poly r(C)-binding protein (PCBP) 1. Mol Cancer Ther. 14:1162–1170. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zhang HY and Dou KF: PCBP1 is an important mediator of TGF-β-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD. Mol Biol Rep. 41:5519–5524. 2014. View Article : Google Scholar : PubMed/NCBI
32	Xue X, Wang X, Liu Y, Teng G, Wang Y, Zang X, Wang K, Zhang J, Xu Y, Wang J and Pan L: SchA-p85-FAK complex dictates isoform-specific activation of Akt2 and subsequent PCBP1-mediated post-transcriptional regulation of TGFβ-mediated epithelial to mesenchymal transition in human lung cancer cell line A549. Tumour Biol. 35:7853–7859. 2014. View Article : Google Scholar : PubMed/NCBI
33	Ghanem LR, Chatterji P and Liebhaber SA: Specific enrichment of the RNA-binding proteins PCBP1 and PCBP2 in chief cells of the murine gastric mucosa. Gene Expr Patterns. 14:78–87. 2014. View Article : Google Scholar : PubMed/NCBI
34	Song Q, Sheng W, Zhang X, Jiao S and Li F: ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549. Tumour Biol. 35:1377–1382. 2014. View Article : Google Scholar : PubMed/NCBI
35	Cho SJ, Jung YS and Chen X: Poly (C)-binding protein 1 regulates p63 expression through mRNA stability. PLoS One. 8:e717242013. View Article : Google Scholar : PubMed/NCBI
36	Shi Z, Zhang T, Long W, Wang X, Zhang X, Ling X and Ding H: Down-regulation of poly(rC)-binding protein 1 correlates with the malignant transformation of hydatidiform moles. Int J Gynecol Cancer. 22:1125–1129. 2012. View Article : Google Scholar : PubMed/NCBI
37	Lian WX, Yin RH, Kong XZ, Zhang T, Huang XH, Zheng WW, Yang Y, Zhan YQ, Xu WX, Yu M, et al: THAP11, a novel binding protein of PCBP1, negatively regulates CD44 alternative splicing and cell invasion in a human hepatoma cell line. FEBS Lett. 586:1431–1438. 2012. View Article : Google Scholar : PubMed/NCBI
38	Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, Lim SG, Zhou J, Chng WJ, Ng SB, et al: PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 18:52–62. 2010. View Article : Google Scholar : PubMed/NCBI
39	Scimeca M, Urbano N, Bonfiglio R, Duggento A, Toschi N, Schillaci O and Bonanno E: Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology. Biochim Biophys Acta Rev Cancer. 1872:138–148. 2019. View Article : Google Scholar : PubMed/NCBI